Research Article
Efficacy Analysis of Combining Sintilimab with Neoadjuvant Chemotherapy in Treating Middle and Advanced Rectal Cancer Based on Big Data
Table 2
Evaluation results of patients’ adverse reactions.
| | Adverse reactions | Grade I | Grade II | Grade III | Grade IV | Grade V | Total incidence rate |
| | Nausea | 17 | 2 | 0 | 0 | 0 | 19 (44.19) | | Vomiting | 15 | 3 | 1 | 0 | 0 | 19 (44.19) | | Diarrhea | 6 | 5 | 0 | 0 | 0 | 11 (25.58) | | Leukopenia | 8 | 4 | 0 | 0 | 0 | 12 (27.91) | | Granulocytopenia | 11 | 4 | 2 | 0 | 0 | 17 (39.53) | | Thrombocytopenia | 3 | 3 | 0 | 0 | 0 | 6 (13.95) | | Mucocutaneous damage | 10 | 4 | 1 | 0 | 0 | 15 (34.88) | | Neurotoxicity | 9 | 2 | 0 | 0 | 0 | 11 (25.58) | | Peripheral phlebitis | 4 | 1 | 0 | 0 | 0 | 5 (11.63) |
|
|
